Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 287

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Short-Term Oral Endothelin-Receptor Antagonist Therapy in Conventionally Treated Patients With Symptomatic Severe Chronic Heart Failure

Sütsch, Gabor, Kiowski, Wolfgang, Yan, Xiao-Wei, Hunziker, Patrick, Christen, Stefan, Strobel, Werner, Kim, Jong-Hun, Rickenbacher, Peter, Bertel, Osmund · 1998 · Circulation

Abstract

Background—The vasoconstrictor peptide endothelin-1 (ET-1) is important for increased vascular tone in patients with chronic heart failure, but the effects of endothelin-receptor blockade in addition to conventional triple therapy are unknown. Methods and Results—Thirty-six men (mean age±SD, 55±8 years) with symptomatic heart failure (NYHA class III; left ventricular ejection fraction, 22.4±4.5%) despite treatment with diuretics, digoxin, and ACE inhibitors received, in a double-blind and randomized fashion, either additional oral bosentan (1.0 g BID; n=24) or placebo (n=12) over 2 weeks. Hemodynamic and hormonal (plasma ET-1, norepinephrine, renin activity, and angiotensin II) measurements were obtained before and repeatedly for 24 hours after administration of bosentan on days 1 and 14. Bosentan was discontinued in 1 patient with symptomatic hypotension, and 2 patients (bosentan group) declined hemodynamic investigations on day 14. Compared with placebo, bosentan on day 1 significantly decreased mean arterial pressure (difference from baseline over 12 hours [95% CIs], −13.9% [−16.0% to −11.7%]), pulmonary artery mean (−12.9% [−17.4% to −8.3%]) and capillary wedge (−14.5% [−20.5% to −8.5%]) pressures, and right atrial pressure (−20.2% [−29.4% to −11.0%]). Cardiac output increased (15.1% [10.7% to 19.7%]), but heart rate was unchanged. Both systemic (−24.2% [−28.1% to −20.3%]) and pulmonary (−19.9% [−28.4% to −11.4%]) vascular resistance were reduced. After 2 weeks, cardiac output had further increased (by 15.2% [10.8% to 19.6%]) and systemic (−9.3% [−12.3% to −6.4%]) and pulmonary (−9.7% [−16.3% to −3.1%]) vascular resistances further decreased compared with day 1. Heart rate remained unchanged. Plasma ET-1 levels increased after bosentan, but baseline levels of the other hormones were unchanged. Conclusions—Additional short-term oral endothelin-receptor antagonist therapy improved systemic and pulmonary hemodynamics in heart failure patients who were symptomatic with standard triple-drug therapy. Further investigations are warranted to characterize the effects of long-term endothelin-receptor antagonist therapy on symptoms, morbidity, and mortality in such patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.98.21.2262

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 287

Metadata

Authors
Sütsch, G., Kiowski, W., Yan, X.-W., Hunziker, P., Christen, S., Strobel, W., Kim, J.-H., Rickenbacher, P., & Bertel, O.
Venue
Circulation
Published
1998-11-24
Volume
98
Issue
21
Pages
2262-2268
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2104825830
Cited by
287
References
21
FWCI
24.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-Term Oral Endothelin-Receptor Antagonist Therapy in Conventionally Treated Patients With Symptomatic Severe Chronic Heart Failure. https://app.cochat.ai/papers/10.1161/01.cir.98.21.2262
The paper
Sütsch, G., Kiowski, W., Yan, X.-W., Hunziker, P., Christen, S., Strobel, W., Kim, J.-H., Rickenbacher, P., & Bertel, O. (1998). Short-Term Oral Endothelin-Receptor Antagonist Therapy in Conventionally Treated Patients With Symptomatic Severe Chronic Heart Failure. Circulation. https://doi.org/10.1161/01.cir.98.21.2262

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.